300723.SHE Yipinhong Pharmaceutical Co Ltd Class A
- Market cap
- CNY 12.7B
- P/E
- 70.0x
- P/B
- 7.09x
- ROE
- 28.8%
- Dividend yield
- 0.45%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300723.SHE undervalued?
Graham numberThe Graham number of Yipinhong Pharmaceutical Co Ltd Class A cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Yipinhong Pharmaceutical Co Ltd Class A fundamental analysis
No fundamental analysis for Yipinhong Pharmaceutical Co Ltd Class A yet.
Yipinhong Pharmaceutical Co Ltd Class A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Yipinhong Pharmaceutical Co Ltd Class A
ApicHope Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceuticals in China. The company offers pediatric medicines; chronic disease drugs; active pharmaceutical ingredients and formulations; and specialty traditional Chinese medicines. It is also involved in scientific research and technical services; wholesale and retail trade; information technology; and technology promotion and applicatio…
Full company profileYipinhong Pharmaceutical Co Ltd Class A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Yipinhong Pharmaceutical Co Ltd Class A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.25B | 1.38B | 1.43B | 1.64B | 1.68B | 2.20B | 2.28B | 2.50B | 1.45B | 932M | 822M |
| Gross Profit | 650M | 797M | 1.03B | 1.27B | 1.38B | 1.88B | 1.98B | 2.02B | 874M | 527M | 419M |
| Operating Income | 142M | 182M | 235M | 182M | 199M | 285M | 282M | 214M | -371M | -250M | -245M |
| EBITDA | 191M | 222M | 253M | 202M | 225M | 306M | 366M | 387M | -116M | -96.7M | 517M |
| Net Income | 137M | 157M | 208M | 144M | 226M | 307M | 291M | 185M | -540M | -338M | 510M |
| EPS | 0.42 | 0.47 | 0.48 | 0.33 | 0.52 | 0.71 | 0.69 | 0.42 | -1.20 | -0.75 | 1.13 |
| Balance Sheet | |||||||||||
| Total Assets | 752M | 1.48B | 1.78B | 1.79B | 2.15B | 3.70B | 4.10B | 4.41B | 4.40B | 4.04B | 4.32B |
| Total Liabilities | 416M | 373M | 482M | 454M | 650M | 1.69B | 1.93B | 1.81B | 2.47B | 2.64B | 2.51B |
| Shareholders' Equity | 333M | 1.11B | 1.30B | 1.33B | 1.48B | 1.87B | 2.05B | 2.52B | 1.88B | 1.37B | 1.77B |
| Cash & Short-term Investments | 94.2M | 85.0M | 752M | 746M | 739M | 1.09B | 718M | 463M | 474M | 515M | 1.13B |
| Total Debt | 319M | 251M | 279M | 198M | 290M | 1.23B | 1.17B | 736M | 1.61B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 146M | 141M | 239M | 281M | 275M | 438M | 476M | 458M | -550M | 46.0M | - |
| Capital Expenditure | 28.6M | 28.5M | 257M | 105M | 314M | 561M | 606M | 334M | 320M | 127M | 50.4M |
| Free Cash Flow | 117M | 113M | -18.2M | 175M | -38.9M | -123M | -130M | 124M | -870M | -81.2M | 32.3M |
| Ratios | |||||||||||
| ROE | 41.2% | 14.2% | 16.0% | 10.8% | 15.2% | 16.4% | 14.2% | 7.3% | -28.7% | -24.7% | 28.8% |
| ROA | 18.3% | 10.6% | 11.7% | 8.0% | 10.5% | 8.3% | 7.1% | 4.2% | -12.3% | -8.4% | 11.8% |
| Net Profit Margin | 11.0% | 11.4% | 14.6% | 8.8% | 13.5% | 14.0% | 12.7% | 7.4% | -37.2% | -36.2% | 62.1% |
| Debt to Equity | 0.96x | 0.23x | 0.22x | 0.15x | 0.20x | 0.66x | 0.57x | 0.29x | 0.86x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Yipinhong Pharmaceutical Co Ltd Class A dividends
- Dividend yield
- 0.45%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jun 3, 2024
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 56.8M | 0.13 | - |
| 2024 | CNY 108M | 0.24 | - |
| 2023 | CNY 56.6M | 0.13 | 30.7% |
| 2022 | CNY 56.6M | 0.13 | 19.5% |
| 2021 | CNY 39.3M | 0.09 | 12.8% |
| 2020 | CNY 31.4M | 0.07 | 13.9% |
| 2019 | CNY 32.2M | 0.07 | 22.4% |
| 2018 | CNY 41.4M | 0.09 | 19.9% |
| 2017 | CNY 15.6M | 0.05 | 9.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.5:1 on May 24, 2023.
Who owns Yipinhong Pharmaceutical Co Ltd Class A
- Insiders 68.16%
- Institutions 1.67%
- Public & others 30.17%
- Shares outstanding 453M
- Free float 160M
Yipinhong Pharmaceutical Co Ltd Class A company profile
- Company name
- Yipinhong Pharmaceutical Co Ltd Class A
- Ticker
- 300723.SHE
- ISIN
- CNE1000035J7
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,294
- Fiscal year end
- December
- Address
- Yunrun Building, Guangzhou, China, 510320
- Phone
- 86 20 2887 7666
- Website
- apichope.com
About Yipinhong Pharmaceutical Co Ltd Class A
ApicHope Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceuticals in China. The company offers pediatric medicines; chronic disease drugs; active pharmaceutical ingredients and formulations; and specialty traditional Chinese medicines. It is also involved in scientific research and technical services; wholesale and retail trade; information technology; and technology promotion and application services. The company was formerly known as ApicHope Pharmaceutical Co., Ltd and changed its name to ApicHope Pharmaceutical Group Co., Ltd. in December 2024. ApicHope Pharmaceutical Group Co., Ltd. was founded in 2002 and is headquartered in Guangzhou, China.
Yipinhong Pharmaceutical Co Ltd Class A management
4- Mr. Hanxiong LiChairman of the Board of Directors & GM · born 1974
- Mr. Huixing ZhangAccounting Supervisor & CFO · born 1966
- Ms. Dongling YangDeputy GM · born 1967
- Mr. Mingyuan ZhangDeputy GM & Secretary of Board · born 1985